An open-label, randomized, single-dose, three-way crossover bioavailability study comparing DFN-02 with subcutaneous sumatriptan in healthy volunteers.
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2016
At a glance
- Drugs DFN 02 (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- 26 Sep 2016 New trial record
- 10 Sep 2016 Results of pooled analysis of effect of permeation enhancer on pharmacokinetics of sumatriptan from this and another trial (CTP 700276590) published in the Headache.